Andrew Cheng, President and CEO at Akero Therapeutics, Inc. (AKRO), sold 52,800 shares at $41.00 ($2.2M) on 2025-05-12, disclosed to the SEC on 2025-05-13.
Scheduled sale ($2.2M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.00 | 7,200 | $295K | 13.5% |
| 2 | $41.63 | 22,800 | $949K | 43.3% |
| 3 | $41.63 | 22,800 | $949K | 43.3% |
| Total | $41.54 avg | 52,800 | $2.2M | 100% |
| Filing → |
| AKRO | SELL | 2025-08-13 | $2.9M | — | Filing → |
| AKRO | SELL | 2025-07-11 | $3.1M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $726K | — | Filing → |